IFP Advisors Inc lifted its stake in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 44.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 178,547 shares of the biopharmaceutical company's stock after purchasing an additional 54,983 shares during the period. IFP Advisors Inc owned 0.11% of TG Therapeutics worth $5,374,000 as of its most recent SEC filing.
Other large investors have also recently modified their holdings of the company. Bleakley Financial Group LLC purchased a new stake in TG Therapeutics in the fourth quarter worth about $245,000. Castellan Group purchased a new position in shares of TG Therapeutics in the 4th quarter valued at approximately $8,539,000. Oppenheimer & Co. Inc. bought a new stake in shares of TG Therapeutics during the third quarter valued at approximately $759,000. Segall Bryant & Hamill LLC purchased a new stake in TG Therapeutics in the third quarter worth $1,225,000. Finally, Barclays PLC raised its holdings in TG Therapeutics by 83.9% in the third quarter. Barclays PLC now owns 347,057 shares of the biopharmaceutical company's stock worth $8,117,000 after purchasing an additional 158,323 shares in the last quarter. Institutional investors own 58.58% of the company's stock.
Wall Street Analysts Forecast Growth
Several research analysts recently issued reports on TGTX shares. JPMorgan Chase & Co. increased their price target on shares of TG Therapeutics from $30.00 to $43.00 and gave the stock an "overweight" rating in a research note on Monday, November 25th. StockNews.com lowered shares of TG Therapeutics from a "hold" rating to a "sell" rating in a report on Friday, January 31st. The Goldman Sachs Group raised their price objective on TG Therapeutics from $20.00 to $22.00 and gave the company a "neutral" rating in a research report on Tuesday, November 5th. Finally, HC Wainwright reissued a "buy" rating and issued a $55.00 target price on shares of TG Therapeutics in a report on Wednesday, January 15th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, TG Therapeutics currently has an average rating of "Moderate Buy" and an average price target of $40.67.
Check Out Our Latest Research Report on TG Therapeutics
TG Therapeutics Stock Up 5.5 %
TGTX stock traded up $1.56 during midday trading on Friday, hitting $30.09. The company's stock had a trading volume of 2,407,379 shares, compared to its average volume of 2,157,544. The firm's 50-day moving average is $30.79 and its 200-day moving average is $27.98. The company has a current ratio of 4.59, a quick ratio of 3.91 and a debt-to-equity ratio of 1.27. TG Therapeutics, Inc. has a 12 month low of $12.93 and a 12 month high of $36.84. The company has a market cap of $4.68 billion, a PE ratio of -300.87 and a beta of 2.26.
Insider Activity
In other TG Therapeutics news, CFO Sean A. Power sold 10,021 shares of the business's stock in a transaction on Monday, January 6th. The shares were sold at an average price of $28.53, for a total transaction of $285,899.13. Following the completion of the sale, the chief financial officer now directly owns 660,611 shares in the company, valued at approximately $18,847,231.83. The trade was a 1.49 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 10.50% of the company's stock.
About TG Therapeutics
(
Free Report)
TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.
Featured Stories
Before you consider TG Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TG Therapeutics wasn't on the list.
While TG Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
